News & Press Releases

PneumRx, a BTG International group company, is focused on developing minimally invasive solutions for unmet medical needs in pulmonary medicine. Please click on a link below to learn more about PneumRx and PneumRx Coils, or to find us at our next conference or event.


PneumRx, Inc. Receives FDA Approval to Commence Pivotal Clinical Trial of RePneu Lung Volume Reduction System

May 15, 2012

PneumRx, Inc. (, a medical device company dedicated to bringing innovation and improvements to the treatment of lung disease, today announced that it has received FDA approval to commence a 30-site pivotal clinical trial to support a PMA application for the RePneu LVRC System.

Read Press Release

PneumRX, Inc. Raises $33 Million in Capital

January 04, 2011

Funds will be used to support European sales of the PneumRx RePneu Lung Volume Reduction Coil (LVRC) System and to conduct a Pivotal Clinical Trial to support a PMA Application.

Read Press Release

PneumRx Gets CE Mark for Lung Volume Reduction Coil System

October 13, 2010

PneumRX has received CE Marking for its RePneu Lung Volume Reduction Coil System to treat late stage emphysema. The device is designed to implant coils into the lungs to compress damaged tissue and restore elasticity in healthier lung tissue. The system is a minimally invasive alternative to surgery, according to the company. PneumRX intends to launch the product in Europe later this year.

Read Press Release